The medical technology industry in Australia is crucial for the economy, but there is a need to address challenges in attracting talent and promoting innovation in order to support its growth and potential, according to an extensive report on medical technology in Australia.
In June 2023 the Medical Technology Association of Australia (MTAA) launched The Value of MedTech Report – a major study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and the Australian economy.
The report was prepared using analysis by the Nous Group for the Medical Technology Association of Australia with support from MTPConnect and Pathology Technology Australia.
As part of MTAA’s annual MedTech on the Hill initiative, the report was formally launched in June 2023 by the Minister for Health and Aged Care, the Hon. Mark Butler MP, in Parliament House during an event attended by Ministers, Members of Parliament, Senators, and key health sector stakeholders.
The Report brings to light the significant value and contribution of MedTech in Australia, particularly to Australia’s healthcare system, industry development, employment and the wider economy.
Australian Health Journal spoke with MTAA CEO, Ian Burgess and MTAA Policy Manager, Pravin Siriwardena about the report and its key findings.
About MTAA
The Medical Technology Association of Australia (MTAA) is the national association representing companies in the medical technology industry. MTAA aims to ensure the benefits of modern, innovative and reliable medical technology are delivered effectively to provide better health outcomes to the Australian community.
MTAA represents manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and management of disease and disability. The range of medical technology is diverse with products ranging from familiar items such as syringes and wound dressings, through to high-technology implanted devices such as pacemakers, defibrillators, hip and other orthopaedic implants. Products also include hospital and diagnostic imaging equipment such as ultrasounds and magnetic resonance imaging machines.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
-
MTAA MedTech19 Annual Conference
MTAA’s annual conference is the premier medical technology industry conference in Australia and brings together leaders and influencers across industry, government and academia to discuss what’s up ahead for the MedTech industry.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
